Drug Profile
CYT 108
Alternative Names: A2M - Cytonics; Cyt-108; CYT108; Recombinant A2M - Cytonics; α-2 macroglobulin - Cytonics; α2M - CytonicsLatest Information Update: 21 Feb 2024
Price :
$50
*
At a glance
- Originator Cytonics Corporation
- Class Antirheumatics; Foot disorder therapies; Recombinant proteins
- Mechanism of Action Peptide hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Osteoarthritis
Highest Development Phases
- Preclinical Osteoarthritis
- No development reported Diabetic foot ulcer
Most Recent Events
- 16 Feb 2024 CYT 108 is still in preclinical development in Osteoarthritis in USA (Intra-articular) (NCT06263270)
- 16 Feb 2024 Cytonics Corporation plans phase I trial in Osteoarthritis in Australia (intra-articular) in March 2024 (NCT06263270)
- 28 Jan 2024 No recent reports of development identified for preclinical development in Diabetic-foot-ulcer in USA